Head of Innovative Medicines Initiatives argues that the project’s technologies, knowledge and networks came together in the crisis. The successor programme must sustain these achievements and build on them
The COVID-19 crisis has hammered home the extent of EU dependence on Chinese and US digital technologies. To turn the tide, the emphasis must be on frontier research and translating the outputs to products and jobs
The flaws in Europe’s healthcare systems have been cruelly exposed by COVID-19, experts tell a Science|Business Webcast conference. As lockdowns begin to lift, critical gaps and fault lines must be addressed to increase preparedness for the next big shock
Talent mobility can involve crossing borders – but there are lots of other ways the EU could promote movement of smart people, a Science|Business conference heard. Targeted measures are needed in Horizon Europe
Insistence on excellence in its grant selections has made the European Research Council a leading global brand. But there are lots of ways to define what excellence is, a Science|Business conference hears.
Employees are lukewarm on new locations and a slow-down in work rate will mean less income. In the best case scenario Europe’s drugs regulator will take 2-3 years to get back to speed after leaving London.
Don’t mention the B word: the first major reform of R&D funding since 1965 aims to make the UK the “go-to place” for science. But in setting out the vision, no reference was made to Brexit and its implications
As more health data gets stored and analysed, the challenges of governance and culture stand in the way of progress, a Science|Business Healthy Measures conference heard. A solution: citizen involvement